This technology is a RAGE (Receptor for Advanced Glycated Endproducts) fusion protein that can be used as an effective therapy for RAGE-mediated diseases by antagonistically binding RAGE ligands with high affinity and specificity.
Increased levels of RAGE and its ligand, Advanced Glycosylation Endproducts (AGE), are associated with a wide breadth of pathologies including cardiovascular disease, coronary artery disease, diabetes, chronic inflammation, nephropathy, arteriosclerosis, retinopathy, and Alzheimer’s Disease. RAGE-AGE ligand binding induces both oxidative stress and inflammation, therefore, antagonists of this interaction are desirable for therapeutically treating RAGE-mediated diseases. Current treatments attempt to reduce binding using soluble RAGE; however, the limited half-life of this drug treatment reduces its practicality as a viable therapeutic option. Furthermore, other pharmacological treatments aim at preventing AGE formation, but there are limited drug therapies that effectively, stably, and safely prevent RAGE activation by blocking RAGE-ligand binding.
This technology is a framework for producing RAGE fusion proteins by combining a RAGE polypeptide sequence with a non-RAGE immunoglobulin domain. The ability of these proteins to bind RAGE with high affinity enables effective antagonism of RAGE-ligand interactions, preventing downstream pathologies associated with RAGE activation. These fusion proteins offer an appealing pharmaceutical treatment for reducing RAGE-ligand binding and reducing symptoms of RAGE-mediated diseases.
Ann Marie Schmidt, M.D.
IR Proxy35
Licensing Contact: Jerry Kokoshka
